Skip to main content
Oxford University Press - PMC COVID-19 Collection logoLink to Oxford University Press - PMC COVID-19 Collection
. 2022 Jul 2:dxac031. doi: 10.1093/intimm/dxac031

Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021

Kun Xu 1,2, Chunxiang Fan 3, Yuxuan Han 4, Lianpan Dai 5,6,7, George F Gao 8,9,
PMCID: PMC9278184  PMID: 35778913

Abstract

The unprecedented coronavirus disease 2019 (COVID-19) pandemic has caused a disaster for public health in the last 2 years, without any sign of an ending. Various vaccines were developed rapidly as soon as the outbreak occurred. Clinical trials demonstrated the reactogenicity, immunogenicity and protection efficacy in humans, and some of the vaccines have been approved for clinical use. However, waves of infections such as the recently circulating Omicron variant still occur. Newly emerging variants, especially the variants of concern, and waning humoral responses pose serious challenges to the control of the COVID-19 pandemic. Previously, we summarized the humoral and cellular immunity, safety profiles and protection efficacy of COVID-19 vaccines with clinical data published by 21 May 2021. In this review, we summarize and update the published clinical data of COVID-19 vaccines and candidates up to December 31, 2021.

Keywords: antibody, SARS-CoV-2, vaccine effectiveness, vaccine efficacy, cellular immune response


Articles from International Immunology are provided here courtesy of Oxford University Press

RESOURCES